AGEN
BuyFull HouseAI neutralAgenus Inc. · Healthcare · United States · $286M cap · $6.4M/day traded
$6.16 -2.7% · close 26 Oct · scored 27 Oct
StockRank down 2.2 since 24 Oct.
Full House: Strong business, sensible price, market agrees. The rare full house.
As of 27 Oct 2026, MoatMap's StockRank for Agenus Inc. (AGEN) is 67/100, ranked against 24,000+ stocks in 35 markets (Quality 53, Value 58, Momentum 51, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Agenus is a clinical-stage biotech developing the botensilimab plus balstilimab combination for colorectal, ovarian and other cancers. Recent publications report durable survival in MSS colorectal cancer and deep responses in early colon cancer, and three-year ovarian survival data is due to be presented. The company does not have an approved product, has a long history of losses and has repeatedly raised capital, so its value depends on regulatory and financing outcomes that are hard to predict.
ABOUT AGENUS INC.
Read
Agenus Inc. is a clinical-stage immuno-oncology company focused on discovering and developing novel antibodies and cell therapies to treat cancer, including checkpoint modulators and cancer vaccines. The company's competitive moat is built on its proprietary technology platforms and extensive intellectual property, supported by strategic partnerships with major pharmaceutical firms, positioning it in the cutting-edge field of cancer immunotherapy.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 98.0M | 156.3M | 103.5M | 114.2M | 5.2% | 132.7M | 125.2M | 116.0M | 0.8% |
| EPS | -5.74 | -6.51 | -10.59 | 0.00 | — | 2.58 | — | — | — |
| Shares | 41.6M | 41.6M | 23.6M | 35.3M | -15.2% | 45.2M | — | — | — |
| Debt | 78.4M | 88.5M | 94.9M | 55.9M | -10.7% | 40.7M | — | — | — |
| Equity | -61.3M | -160.3M | -326.4M | -271.1M | — | — | — | — | — |
| Op CF | -175.4M | -224.2M | -158.3M | -77.2M | — | -98.5M | — | — | — |
| Inv CF | -33.6M | 3.4M | 27.0K | 1.2M | — | — | — | — | — |
| Fin CF | 95.8M | 119.9M | 122.8M | 36.6M | — | — | — | — | — |
No clear trend: not near its 52-week low, and not in a steady uptrend.
Swung more than 98% of stocks we rank over the past year (120% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AGEN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| AGEN | Agenus Inc.(you) | $286M | 67 | Buy |
| FENC | Fennec Pharmaceuticals Inc. | $353M | 58 | Hold |
| ORMP | Oramed Pharmaceuticals Inc. | $172M | 73 | Buy |
| MDXG | MiMedx Group, Inc. | $571M | 62 | Hold |
| QTTB | Q32 Bio Inc. | $258M | 88 | Strong Buy |
| ICCC | ImmuCell Corporation | $93M | 68 | Buy |
| ABUS | Arbutus Biopharma Corporation | $644M | 81 | Strong Buy |
| SPRO | Spero Therapeutics, Inc. | $65M | 70 | Buy |
| 1521.HK | Frontage Holdings Corporation | $387M | 94 | Strong Buy |
| MGTX | MeiraGTx Holdings plc | $885M | 56 | Hold |
Peer medians: ROE -30.2% · P/E 27.3x · Gross margin 63.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.